This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
—Since the availability of effective chemotherapy for myeloma, most centers have now seen patients who have lived longer than ten years. Dr Blade's patients are of interest in that two of three patients had presented with an intermediate cell mass and none had received prednisone as part of their initial effective therapy. In contrast to the 2% to 4% of patients who survived ten years among those treated prior to 1975 by Dr Kyle, Dr Blade, and myself, more than 10% of currently treated patients should live that long. This progress is attributed to a combination of earlier diagnosis, better control of complications, and more effective cytoreductive programs at diagnosis and relapse.
Alexanian R. Long-term Survival in Multiple Myeloma-Reply. Arch Intern Med. 1986;146(8):1638. doi:10.1001/archinte.1986.00360200217048
Best of JAMA Network 2022
Customize your JAMA Network experience by selecting one or more topics from the list below.